News Pfizer's weekly haemophilia drug backed for NHS use Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions.
News Pfizer bags EU okay for haemophilia drug Hympavzi Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU
News Pfizer rounds out haemophilia portfolio with FDA approval Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.
News AbbVie invests £120m in UK expansion AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
